Ocular Inflammation in Cataract Patients and Response to Treatment With Xiidra

The Incidence of Ocular Inflammation as Defined by the Inflammadry Assay in 250 Consecutive Cataract Patients and Their Response to Treatment With Xiidra

To determine if the use of Xiidra® reduces ocular surface inflammation in preoperative and postoperative cataract patients.

Single-center, prospective, randomized, investigator-initiated study

250 cataract patients, aged 60 or older, will be tested for ocular surface inflammation with the InflammaDry® immunoassay

Patients with bilateral positive MMP-9 will be randomized into a group treated with Xiidra two weeks preoperatively and six weeks postoperatively or a group not treated with Xiidra

The investigator hypothesizes that treatment with Xiidra prior to routine cataract surgery will significantly improve the quality of keratometry readings and BCVA.

Inclusion Criteria:

• Positive for MMP-9 bilaterally as assessed by the Inflammadry assay

Exclusion Criteria:

• Negative Inflammadry assay in either eye
• Active diabetic retinopathy, uncontrolled glaucoma, uncontrolled uveitic inflammation
• Ocular surface diseases that might confound the interpretation of the InflammaDry assay